Moderna, Inc.
MRNA
Positions held
Your positionsMRNA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Moderna's innovative mRNA technology positions it as a leader in the biotechnology industry, with potential applications beyond COVID-19 vaccines.
- In 2023, Moderna generated $6.754 billion in revenue, showcasing its ability to capitalize on its mRNA platform.
- The company's stock has a target mean price of $120.67, indicating potential upside from current levels.
- Moderna faces significant competition in the vaccine market, which could impact its revenue and market share.
- The company's net income for 2025 is projected to be -$2.822 billion, reflecting ongoing financial challenges.
- Moderna's operating margin has been negative, with a -159.94% margin reported for 2025, indicating struggles in profitability.
Fundamentals
| Market cap | $78.65B | Enterprise value | $74.80B | Trailing P/E | — | Forward P/E | -44.27 |
| PEG | — | Price / book | 11.63 | Beta | 1.10 | Dividend yield | 0.00% |
| Revenue growth | 2.1% | Earnings growth | — | Gross margin | -66.0% | Operating margin | -5.6% |
| Profit margin | -141.4% | ROE | -39.0% | ROA | -13.3% | Debt / equity | 0.19 |
| Current ratio | 2.30 | Free cash flow | $299.25M | Analyst recommendation | hold | Mean target | $121.00 |
| 52w high | $212.22 | 52w low | $22.28 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $143M | $389M | $676M | $1.0B | $137M | — |
| Op margin | -569.9% | -356.8% | -126.8% | -25.9% | -662.0% | — |
| Net income | -$782M | -$1.3B | -$826M | -$200M | -$825M | — |
| Gross margin | 35.0% | -145.5% | 33.1% | 79.3% | 13.1% | — |
| Gross profit | $50.0M | -$566M | $224M | $795M | $18.0M | — |
| Operating income | -$815M | -$1.4B | -$857M | -$260M | -$907M | — |
- Revenue -63% vs prior quarter ($143M vs $389M).
- Gross margin 35% (was -145.5% prior quarter).
- Operating margin compressed to -569.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $1.9B | $3.2B | $6.8B | $18.9B |
| Op margin | -159.9% | -123.3% | -62.8% | 49.9% |
| Net income | -$2.8B | -$3.6B | -$4.7B | $8.4B |
| Gross margin | 54.8% | 54.2% | 30.5% | 71.3% |
| Gross profit | $1.1B | $1.7B | $2.1B | $13.5B |
| Operating income | -$3.1B | -$3.9B | -$4.2B | $9.4B |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies
2026-10-09 · Sector Update: Healthcare Stocks Gain Friday Afternoon
2026-10-09 · Sector Update: Healthcare
2026-10-09 · Moderna stock jumps on planned national cancer vaccine effort
2026-10-09 · Top Midday Gainers
2026-10-09 · Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
2026-10-09 · Market Chatter: Moderna, Other Vaccine Developer Stocks Rise as NIH Plans to Expedite Cancer Vaccines
2026-10-09 · BofA Securities Adjusts Price Target on Moderna to $200 From $170, Maintains Neutral Rating
2026-10-09 · Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development
2026-10-09 · Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development
2026-10-09 · Moderna (MRNA) Was Removed From the Nasdaq-100 and Is Going Back In. What Changed?
2026-10-08 · eClinical Solutions Turns Clinical Data Intelligence Into Action at ENGAGE 2026
Price (daily)
Full chart · RSI · MACD · patternsOn Trade and Ticker